Annals of Indian Academy of Neurology
  Users Online: 2272 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size

Table of Contents
LETTER TO THE EDITOR
Year : 2018  |  Volume : 21  |  Issue : 1  |  Page : 85-87
 

Chronic lymphocytic leukemia involvement of central nervous system: Clinical diversity, diagnostic algorithm and therapeutic challenges


1 Clinic of Haematology, Clinical Centre of Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
2 Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia

Date of Web Publication29-Mar-2018

Correspondence Address:
Prof. Milena Todorovic Balint
Clinic of Haematology, Clinical Centre of Serbia, Koste Todorovica 2 Street, 11000 Belgrade
Serbia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aian.AIAN_442_17

Rights and Permissions

 



How to cite this article:
Mihaljevic B, Smiljanic M, Antic D, Kurtovic NK, Balint MT. Chronic lymphocytic leukemia involvement of central nervous system: Clinical diversity, diagnostic algorithm and therapeutic challenges. Ann Indian Acad Neurol 2018;21:85-7

How to cite this URL:
Mihaljevic B, Smiljanic M, Antic D, Kurtovic NK, Balint MT. Chronic lymphocytic leukemia involvement of central nervous system: Clinical diversity, diagnostic algorithm and therapeutic challenges. Ann Indian Acad Neurol [serial online] 2018 [cited 2019 Dec 10];21:85-7. Available from: http://www.annalsofian.org/text.asp?2018/21/1/85/228843




Sir,

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, but extranodal involvement is rare, as previously reported in 4 and 30 patients, respectively.[1],[2] Neurologic complications are reported in only 1% of patients with CLL.[3] Nevertheless, some previous autopsy studies reported central nervous system (CNS) involvement to be far more frequent, suggesting that it can be underdiagnosed.[3] Diagnostic includes clinical examination, cerebrospinal fluid (CSF) cytology, magnetic resonance imaging, and additional CSF flow cytometric immunophenotyping (FCI) since CSF cytology is of low sensitivity.[4] Here, we present four CLL patients with CNS involvement in which the most common neurological symptoms were headaches, mental status changes, cranial nerve abnormalities, cerebellar symptomatology, lower and upper limbs weakness, and optic neuropathies. All our patients were males with an average age of 55.2 years. Average latency period from diagnosis of CLL to CNS symptomatology onset was 2.9 years. In all cases, CNS involvement was treated with systemic chemotherapeutics plus intrathecal therapy. Radiotherapy was not applied due to either poor general condition or severe thrombocytopenia. Median overall survival from CNS leukemia onset was 3.5 months, with lethal outcome in 75% of patients. General patients characteristics are summarized in [Table 1], in which is obvious that all of them had an advanced disease stage at presentation. Moreover, when CNS infiltration in CLL patients was diagnosed, CSF biochemistry and microbiology showed normal findings, despite of the presence of CLL neoplastic cells (3%–17%) in CSF detected by CSF-FCI [Figure 1]. This is consistent with the fact that a diagnostic “gold standard” of CNS involvement in CLL is CSF cytology, with excellent specificity (>95%), but lower sensibility in up to 60% of explored cases.[5] Besides, the correlation between CNS involvement and presence of neurological symptoms in CLL is not always obvious, regarding the fact that many of these patients have never presented with any neurological symptoms. No specific risk factor for CNS involvement has been identified yet, and in that context, the number of leukocytes at diagnosis had no influence on the occurrence of CNS infiltration. Even though the presence of infectious agents can affect destabilization of hematoencephalic barrier, it was not verified in our patients.
Table 1: General patient's characteristics

Click here to view
Figure 1: Two-parameter dot blot histograms representing CSF FCI analysis in all patients: a) CSF specimen characteristics according to forvard scatter (FSC) vs. side scatter (SSC); b) CSF specimen characteristics according to CD45 vs. SSC; c) population of CLL cells detected in CSF specimen according to specific immunophenotype and low SSC – CD19+CD5+highCD45+high/SSClow

Click here to view


Concerning standard therapeutic approaches, no significant difference in long-term outcome was observed with intrathecal therapy versus radiotherapy versus intrathecal plus radiotherapy. Some systemic chemotherapy regimens such as fludarabine, cycplophosphamide, or bendamustine, combined with rituximab with/without intrathecal therapy significantly improved clinical course, especially high effective bruton tyrosine kinase inhibitor-ibrutinib.[2]

In view of the poor prognosis in these patients, prompt recognition of even a slight occurrence of neurological symptoms in CLL is an imperative for appropriate diagnosis of CNS involvement, whereas the implementation of CSF-FCI as a routine diagnostic tool may be of a great importance, due to its high sensitivity.

Financial support and sponsorship

This work was supported by Ministry of Education, Science and Technological Development, Republic of Serbia (Grant No. III41004).

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Szczepanek D, Wąsik-Szczepanek E, Szymczyk A, Wach M, Cioch M, Podhorecka M, et al. Central nervous involvement by chronic lymphocytic leukaemia. Neurol Neurochir Pol 2017. pii: S0028-3843(17)30323-7.  Back to cited text no. 1
    
2.
Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, et al. Management of central nervous system involvement in chronic lymphocytic leukaemia: A retrospective cohort of 30 patients. Br J Haematol 2017;176:37-49.  Back to cited text no. 2
[PUBMED]    
3.
Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M, et al. Chronic lymphocytic leukemia with central nervous system involvement: A high-risk disease? Clin Lymphoma Myeloma Leuk 2013;13:338-41.  Back to cited text no. 3
    
4.
Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results. Cancer 1998;82:733-9.  Back to cited text no. 4
    
5.
de Souza SL, Santiago F, Ribeiro-Carvalho Mde M, Arnóbio A, Soares AR, Ornellas MH, et al. Leptomeningeal involvement in B-cell chronic lymphocytic leukemia: A case report and review of the literature. BMC Res Notes 2014;7:645.  Back to cited text no. 5
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article

    

 
   Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (1,048 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1025    
    Printed26    
    Emailed0    
    PDF Downloaded50    
    Comments [Add]    

Recommend this journal